Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

Status Recruiting

Clinical Trial Summary

The main purpose of this study is to determine the effectiveness of the study drug pacritinib in people with relapsed or refractory lymphoproliferative disorders.

Clinical Trial Description

Patients will receive single-agent treatment with pacritinib 200mg orally twice daily until any condition for treatment discontinuation has been met. Patients will be enrolled into one of four cohorts: Peripheral T-Cell Lymphoma, not otherwise specified (PTCL, NOS) (cohort 1); angioimmunoblastic T-cell lymphoma/follicular helper T-cell (AITL/TFH) PTCL (cohort 2); Cutaneous T-Cell Lymphoma (CTCL) - mycosis fungoides (MF) and Sezary syndrome (SS) (cohort 3); and other eligible, less common PTCL subtypes (cohort 4). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04858256
Study type	Interventional
Source	University of Michigan Rogel Cancer Center
Contact
Status	Recruiting
Phase	Phase 2
Start date	March 29, 2023
Completion date	November 2028

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03663933` - Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation	Phase 2
Recruiting	`NCT04339777` - Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity	Phase 2
Not yet recruiting	`NCT05969821` - Clonal Hematopoiesis of Immunological Significance
Enrolling by invitation	`NCT01728402` - Pathogenesis of Hematologic Malignancies
Completed	`NCT00068146` - Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma
Recruiting	`NCT03340155` - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases	N/A
Recruiting	`NCT05770102` - DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition	Phase 2/Phase 3
Completed	`NCT03744676` - A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)	Phase 2
Recruiting	`NCT02579967` - Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies	Phase 2
Recruiting	`NCT05803616` - Liquid Biopsy to Enable Diagnostics and Monitoring for Immune-mediated Lymphoproliferative Disorders
Recruiting	`NCT02505789` - Transfusion-related EBV Infection Among Allogeneic Stem Cell Transplant Pediatric Recipients	N/A
Withdrawn	`NCT00968461` - Study of Phenethyl Isothiocyanate in Lymphoproliferative Disorders	Phase 1
Recruiting	`NCT01186224` - Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC)	N/A
Terminated	`NCT00992732` - Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders	Phase 2
Completed	`NCT00063648` - Detection and Cytotoxic T Lymphocyte Therapy of Post-Transplant Lymphoproliferative Disorder After Liver Transplant	Phase 1
Terminated	`NCT03601819` - Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders	Phase 1
Active, not recruiting	`NCT04309084` - Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma	Phase 1
Completed	`NCT03397706` - Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies	Phase 1/Phase 2
Withdrawn	`NCT05431179` - A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma	Phase 3
Not yet recruiting	`NCT05001386` - In Vitro Drug Sensitivity Testing of Fresh Human Samples	N/A